- The FDA cleared two AI algorithms to evaluate the success of PVI ablation for complex arrhythmias.
- These tools are available on a price-per-use basis.
CathVision announced the FDA clearance and commercial availability of two algorithms as part of its artificial intelligence-powered EP recording system for ECG interpretation.
The company’s suit of AI algorithms (Cardialytics) is integrated into its AI system (ECGenius) and is designed to help improve ablation outcomes in complex atrial arrhythmia procedures by measuring the success of cardiac ablation, according to a company press release.
The first algorithm (PVI Analyzer) is a signal-based AI algorithm designed to confirm pulmonary vein isolation status across multiple cardiac ablation modalities for complex arrhythmias. The other algorithm (Signal Complexity) is designed to help physicians visualize and quantify atrial fibrillation complexity parameters in patients with persistent AF, according to the release.
The tools are available on a price-per-use basis.
RELATED: Medtronic’s spinal cord stimulator receives CE Mark
“CathVision’s technology has taken us back to our roots in cardiac electrophysiology and improved upon critical data that was vastly overlooked for many years,” Larry Chinitz, MD, the Alvin Benjamin and Kenneth Coyle, Sr. Family Professor of Medicine and Cardiac Electrophysiology, and director of the cardiac electrophysiology and heart rhythm center in the Leon H. Charney Division of Cardiology at NYU Langone, said in the release. “With improved signal quality providing accurate and meaningful data, the integration of Cardialytics’ uniquely principled AI tools will continue CathVision’s transformation of electrophysiology.”
